Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-565.61M |
| Operating Margin | 0.00% |
| Return on Equity | -80.10% |
| Return on Assets | -46.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.56 |
| Price-to-Book | 10.99 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -14.12 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $206.55M |
| Float | $91.59M |
| % Insiders | 56.02% |
| % Institutions | 54.01% |
Volatility is currently contracting
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
Immunovant, Inc. (IMVT) Q1 2027 Earnings Call Transcript
Roivant said its first quarter was relatively quiet operationally but positioned the company for a more active second half of 2026, with a potential launch of brepocitinib in dermatomyositis, multiple clinical readouts and further updates from Immunovant NASDAQ: IMVT.
IMVT posts a wider quarterly loss as R&D spending rises, but its cash runway supports IMVT-1402 through a planned Graves' disease commercial launch.
All IMVT-1402 clinical development timelines remain on track, including ongoing studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), difficult-to-treat rheumatoid arthritis (D2T RA), Sjögren's disease (SjD) and cutaneous lupus erythematosus (CLE) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 6, 2026 DURHAM, N.C.
I initiate coverage of Immunovant with a BUY rating and a $50 price target, driven by optimism around IMVT-1402's differentiated profile. IMVT-1402 demonstrates strong IgG reduction with minimal albumin and LDL impact, potentially best-in-class, with Graves' disease as the principal valuation driver. My valuation assumes ~$4B probability-adjusted peak sales and a conservative 2.5x sales multiple, supporting a ~$10.9B equity value, or $50 per share.
NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IMVT and any ticker you trade — then tracks every position and per-strategy win rate.
